## 1-Adamantanol: A Versatile Scaffold for Research
1-Adamantanol is a **rigid, tricyclic alcohol** with the molecular formula C₁₀H₁₆O. Its unique structure and properties make it a valuable compound in various fields of research.
**Key Characteristics:**
* **Rigid Structure:** The adamantane core provides a rigid framework, which minimizes conformational flexibility and allows for precise structural control.
* **Hydrophobic Nature:** The hydrocarbon backbone makes 1-adamantanol hydrophobic, facilitating interactions with non-polar environments.
* **Functional Group:** The hydroxyl group provides a versatile handle for chemical modifications and reactions.
**Research Applications:**
1-Adamantanol finds use in diverse areas, including:
* **Medicinal Chemistry:**
* **Drug Design:** Its rigid structure serves as a scaffold for designing potent and selective drug molecules.
* **Pharmacological Studies:** 1-adamantanol derivatives exhibit diverse biological activities, such as antiviral, antibacterial, and anti-inflammatory properties.
* **Materials Science:**
* **Polymers:** 1-adamantanol can be incorporated into polymers to improve their mechanical properties, thermal stability, and hydrophobicity.
* **Nanomaterials:** It can be used as a building block for synthesizing novel nanomaterials with tailored properties.
* **Organic Chemistry:**
* **Synthesis:** Its robust structure and functional group make it a valuable building block in organic synthesis.
* **Catalyst Development:** 1-adamantanol can be used as a ligand or scaffold for designing novel catalysts.
* **Analytical Chemistry:**
* **Chromatography:** Its hydrophobic nature makes it useful as a stationary phase in chromatography.
* **Spectroscopy:** Its unique structure provides distinct spectroscopic signals, aiding in compound identification.
**Specific Examples:**
* **Amantadine:** A derivative of 1-adamantanol, amantadine is an antiviral drug used to treat influenza A.
* **Memantine:** Another derivative, memantine, is a drug used to treat Alzheimer's disease.
* **Adamantane-Based Polymers:** Polymers containing adamantane units exhibit improved thermal stability and mechanical properties.
**Conclusion:**
1-Adamantanol, with its unique structural and chemical properties, is a versatile scaffold for various research applications. Its use in medicinal chemistry, materials science, and organic chemistry highlights its importance in advancing scientific understanding and developing new technologies.
| ID Source | ID |
|---|---|
| PubMed CID | 64152 |
| CHEMBL ID | 2041310 |
| SCHEMBL ID | 148421 |
| SCHEMBL ID | 14473233 |
| SCHEMBL ID | 23333268 |
| MeSH ID | M0397925 |
| Synonym |
|---|
| HMS1758O22 |
| AC-16092 |
| nsc 108837 |
| nsc 91633 |
| ai3-61285 |
| tricyclo(3.3.1.13,7)decan-1-ol |
| tricyclo(3.3.1.1(sup 3,7))decan-1-ol |
| einecs 212-202-8 |
| tricyclo[3.3.1.1(3,7)]decan-1-ol |
| SDCCGMLS-0066229.P001 |
| nsc-91633 |
| nsc91633 |
| nsc-108837 |
| 1-hydroxyadamantane |
| 1-adamantanol , |
| 768-95-6 |
| tricyclo[3.3.1.13,7]decan-1-ol |
| 1-adamantol |
| nsc108837 |
| inchi=1/c10h16o/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9,11h,1-6h |
| tricyclo[3.3.1.1~3,7~]decan-1-ol |
| adamantan-1-ol |
| 1-adamantanol, reagentplus(r), 99% |
| STK387538 |
| A0939 |
| AKOS000264926 |
| 1-(1-adamantyl)-3-(dimethylamino)propan-1-ol hydrochloride |
| A838888 |
| AKOS004908005 |
| CHEMBL2041310 |
| p9j0b0c8zb , |
| unii-p9j0b0c8zb |
| FT-0607301 |
| PS-4604 |
| AKOS015904444 |
| BBL033940 |
| hydroxyadamantane |
| adamantane-1-ol |
| 1 -adamantanol |
| 1-admantanol |
| adamantyl alcohol |
| SCHEMBL148421 |
| DTXSID10227620 |
| SCHEMBL14473233 |
| VLLNJDMHDJRNFK-CHIWXEEVSA-N |
| adamantol-(1) |
| 1-adamantyl alcohol |
| tricyclo(3.3.1.1(3,7))-n-decanol |
| W-104337 |
| STR07597 |
| CS-W020580 |
| mfcd00074729 |
| 1-adamantanol, purum, >=99.0% (gc) |
| 1-adamantanol, vetec(tm) reagent grade, 98% |
| SY010553 |
| Z56771134 |
| F0701-0170 |
| AMY25777 |
| SCHEMBL23333268 |
| EN300-16775 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID668904 | Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4 | Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
| AID1661728 | Binding affinity to HSA assessed as free fraction by HPLC analysis | 2020 | ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8 | Systematic Investigation of the Permeability of Androgen Receptor PROTACs. |
| AID668906 | Inhibition of Influenza A Virus M2 proton channel S31N mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4 | Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
| AID1123154 | Hypobetalipoproteinemic activity in diet-induced hypercholesteremic rat model assessed as decrease in total serum cholesterol at 50 mg/kg, po relative to control | 1979 | Journal of medicinal chemistry, Jan, Volume: 22, Issue:1 | Hypobetalipoproteinemic agents. 2. Compounds related to 4-(1-adamantyloxy)aniline. |
| AID668905 | Inhibition of Influenza A Virus M2 proton channel V27A mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4 | Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
| AID1123155 | Hypobetalipoproteinemic activity in diet-induced hypercholesteremic rat model assessed as decrease in heparin precipitating lipoproteins at 50 mg/kg, po relative to control | 1979 | Journal of medicinal chemistry, Jan, Volume: 22, Issue:1 | Hypobetalipoproteinemic agents. 2. Compounds related to 4-(1-adamantyloxy)aniline. |
| AID1123157 | Toxicity in diet-induced hypercholesteremic rat model assessed as increase in body weight at 50 mg/kg, po relative to control | 1979 | Journal of medicinal chemistry, Jan, Volume: 22, Issue:1 | Hypobetalipoproteinemic agents. 2. Compounds related to 4-(1-adamantyloxy)aniline. |
| AID1661729 | Chromatographic hydrophobicity index, log D of the compound at pH 7.4 by HPLC analysis | 2020 | ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8 | Systematic Investigation of the Permeability of Androgen Receptor PROTACs. |
| AID668903 | Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay | 2011 | ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4 | Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. |
| AID1123158 | Toxicity in diet-induced hypercholesteremic rat model assessed as increase in food intake at 50 mg/kg, po relative to control | 1979 | Journal of medicinal chemistry, Jan, Volume: 22, Issue:1 | Hypobetalipoproteinemic agents. 2. Compounds related to 4-(1-adamantyloxy)aniline. |
| AID1123156 | Selectivity ratio of T/C for heparin precipitating lipoproteins to T/C for total serum cholesterol in diet-induced hypercholesteremic rat model | 1979 | Journal of medicinal chemistry, Jan, Volume: 22, Issue:1 | Hypobetalipoproteinemic agents. 2. Compounds related to 4-(1-adamantyloxy)aniline. |
| AID1661727 | Apparent permeability in pH 7.4 ammonium acetate buffer incubated for 5 hrs by PAMPA | 2020 | ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8 | Systematic Investigation of the Permeability of Androgen Receptor PROTACs. |
| AID1661730 | Protac activity at VHL/androgen receptor in human LNCaP cells assessed as induction of androgen receptor protein degradation at 1 uM incubated for 6 hrs by Western blot analysis relative to control | 2020 | ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8 | Systematic Investigation of the Permeability of Androgen Receptor PROTACs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||